Timing of birth and adverse pregnancy outcomes in cases of prenatally diagnosed vasa previa: a systematic review and meta-analysis.


Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
08 2022
Historique:
received: 27 11 2021
revised: 06 03 2022
accepted: 06 03 2022
pubmed: 15 3 2022
medline: 27 7 2022
entrez: 14 3 2022
Statut: ppublish

Résumé

The ideal time for birth in pregnancies diagnosed with vasa previa remains unclear. We conducted a systematic review aiming to identify the gestational age at delivery that best balances the risks for prematurity with that of pregnancy prolongation in cases with prenatally diagnosed vasa previa. Ovid MEDLINE, PubMed, CINAHL, Embase, Scopus, and Web of Science were searched from inception to January 2022. The intervention analyzed was delivery at various gestational ages in pregnancies prenatally diagnosed with vasa previa. Cohort studies, case series, and case reports were included in the qualitative synthesis. When summary figures could not be obtained directly from the studies for the quantitative synthesis, authors were contacted and asked to provide a breakdown of perinatal outcomes by gestational age at birth. Study appraisal was completed using the National Institutes of Health quality assessment tool for the respective study types. Statistical analysis was performed using a random-effects meta-analysis of proportions. The search identified 3435 studies of which 1264 were duplicates. After screening 2171 titles and abstracts, 140 studies proceeded to the full-text screen. A total of 37 studies were included for analysis, 14 of which were included in a quantitative synthesis. Among 490 neonates, there were 2 perinatal deaths (0.4%), both of which were neonatal deaths before 32 weeks' gestation. In general, the rate of neonatal complications decreased steadily from <32 weeks' gestation (4.6% rate of perinatal death, 91.2% respiratory distress, 11.4% 5-minute Apgar score <7, 23.3% neonatal blood transfusion, 100% neonatal intensive care unit admission, and 100% low birthweight) to 36 weeks' gestation (0% perinatal death, 5.3% respiratory distress, 0% 5-minute Apgar score <7, 2.9% neonatal blood transfusion, 29.2% neonatal intensive care unit admission, and 30.9% low birthweight). Complications then increased slightly at 37 weeks' gestation before decreasing again at 38 weeks' gestation. Prolonging pregnancies until 36 weeks' gestation seems to be safe and beneficial in otherwise uncomplicated pregnancies with antenatally diagnosed vasa previa.

Identifiants

pubmed: 35283090
pii: S0002-9378(22)00177-6
doi: 10.1016/j.ajog.2022.03.006
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-181.e24

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Samantha J Mitchell (SJ)

Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia. Electronic address: sjmitchell013@gmail.com.

Georgia Ngo (G)

Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.

Kimberly A Maurel (KA)

Clinical Services Division, The Mednax Center for Research, Education, Quality and Safety, Sunrise, FL.

Junichi Hasegawa (J)

Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.

Tatsuya Arakaki (T)

Department of Obstetrics and Gynecology, Showa University School of Medicine, Shinagawa-Ku, Tokyo, Japan.

Yaakov Melcer (Y)

Department of Obstetrics and Gynecology, Shamir Medical Center (formerly Assaf Harofeh Medical Center), Be'er Ya'akov, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Ron Maymon (R)

Department of Obstetrics and Gynecology, Shamir Medical Center (formerly Assaf Harofeh Medical Center), Be'er Ya'akov, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Françoise Vendittelli (F)

Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, Institut Pascal, F-63000 Clermont-Ferrand, France.

Alireza A Shamshirsaz (AA)

Division of Fetal Therapy and Surgery, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.

Hadi Erfani (H)

Division of Fetal Therapy and Surgery, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.

Scott A Shainker (SA)

Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA.

Antonio F Saad (AF)

Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX.

Marjorie C Treadwell (MC)

University of Michigan Health, Ann Arbor, MI.

Ashley S Roman (AS)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NYU Langone Health, New York, NY.

Joanne L Stone (JL)

Icahn School of Medicine at Mount Sinai, New York, NY.

Daniel L Rolnik (DL)

Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH